The effects of stresscopin (SCP) on rat paraventricular nucleus (PVN) neurons were examined using whole-cell patch-clamp recordings and single-cell reverse-transcription multiplex polymerase chain reaction (SC-RT-mPCR) techniques. Under current-clamp conditions, bath application of SCP (100 nM) induced inhibition in 35.2% (37/105) of putative magnocellular neurons and 24.7% (20/81) of putative parvocellular neurons, and excitation in 5.7% (6/105) of putative magnocellular neurons and 18.5% (15/81) of putative parvocellular neurons. SCP-induced inhibition persisted in the presence of a mixture of TTX, a voltage-gated Na+ channel blocker, CNQX, an AMPA/kainate receptor antagonist and bicuculline, a GABAA receptor antagonist, whereas SCP-induced excitation of PVN neurons was reversed by the mixture. The SCP-induced inhibition of PVN neurons was abolished by bath application of antisauvagine-30, a selective CRF receptor 2 (CRF-R2) antagonist. Under voltage-clamp conditions, SCP evoked outward currents at the holding potential (？60 mV), which reversed near the potassium equilibrium potential. The SCP-evoked membrane currents were completely blocked by bath application of tertiapin-Q, a selective blocker of G protein-activated inwardly rectifying potassium (GIRK) channels. SC-RT-mPCR analysis indicated that all the SCP-sensitive PVN neurons (57 SCP-inhibited neurons, 21 SCP-excited neurons) expressed CRF-R1 and CRF-R2 mRNAs. Among SCP-hyperpolarized PVN neurons, oxytocin (OT) mRNA was detected in 91.8% of putative magnocellular neurons and 45.0% of putative parvocellular neurons. OT mRNA was also detected in 26.6% of SCP-depolarized parvocellular neurons, but not in SCP-depolarized magnocellular neurons. These results indicate that SCP inhibits a subpopulation of PVN neurons, especially OTergic magnocellular neurons, by enhancing the activity of GIRK channels via CRF-R2.
References
[1]
Lewis K, Li C, Perrin MH, Blount A, Kunitake K, et al. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98: 7570–7575.
[2]
Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7: 605–611.
[3]
Chen R, Lewis KA, Perrin M, Vale WW (1993) Expression cloning of a human cor- ticotropin-releasing factor receptor. Proc Natl Acad Sci USA 90: 8967–8971.
[4]
Li C, Vaughan J, Sawchenko PE, Vale WW (2002) Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 22: 991–1001.
[5]
Frank MD, Rechard LH (2002) The CRF peptide family and their receptors: Yet more partners discovered. Trends in pharmacological sciences 23: 71–77 Review.
[6]
Wong ML, Licinio J, Pasternak KI, Gold PW (1994) Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry. Endocrinology 135: (5) 2275–8.
[7]
Lovenberg TW, Chalmers CW, Liu C, De Souza EB (1995) CRF2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136: 4139–4142.
[8]
Qiu DL, Chu CP, Tsukino H, Shirasaka T, Nakao H, et al. (2005a) Neuromedin U receptor-2 mRNA and HCN channels mRNA expression in NMU-sensitive neurons in rat hypothalamic paraventricular nucleus. Neurosci Lett 374 (1) 69–72.
[9]
Sawchenko PE, Swanson LW, Steinbusch HW, Verhofstad AA (1983) The organization of forebrain afferents to the paraventricular and supraoptic nuclei of the rat. Brain Res 31 277 (2) 355–360.
[10]
Weiss ML, Hatton GI (1990) Collateral input to the paraventricular and supraoptic nuclei in rat. I. Afferents from the subfornical organ and the anteroventral third ventricle region. Brain Res Bull 24: 231–238.
[11]
Jamieson PM, Li C, Kukura C, Vaughan J, Vale W (2006) Urocortin 3 modulates the neuroendocrine stress response and is regulated in rat amygdala and hypothalamus by stress and glucocorticoids. Endocrinology 147 (10) 4578–88.
[12]
Fekete EM, Inoue K, Zhao Y, Rivier JE, Vale WW, et al. (2007) Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval. Neuropsychopharmacology 32 (5) 1052–1068.
[13]
Ohata H, Shibasaki T (2004) Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptides 25 (10) 1703–1709.
[14]
Chao H, Digruccio M, Chen P, Li C (2012) Type 2 corticotropin-releasing factor receptor in the ventromedial nucleus of hypothalamus is critical in regulating feeding and lipid metabolism in white adipose tissue. Endocrinology 153 (1) 166–176.
[15]
Chen P, Vaughan J, Donaldson C, Vale W, Li C (2010) Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis. Am J Physiol Endocrinol Metab 298 (2) E337–345.
[16]
Chu CP, Qiu DL, Kato K, Kunitake T, Watanabe S, et al. (2004) Central stresscopin modulates cardiovascular function through the adrenal medulla in conscious rats. Regul Pept 119: 53–59.
[17]
Hashimoto K, Nishiyama M, Tanaka Y, Noguchi T, Asaba K, et al. (2004) Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Peptides 25 (10) 1711–1721 Review.
[18]
Li X, Fan MX, Shen LL, Cao YX, Zhu DN, et al. (2010) Excitatory responses of cardiovascular activities to urocortin3 administration into the PVN of the rat. Autonomic Neuroscience : Basic and Clinical 154: 108–111.
[19]
Swanson LW, Sawchenko PE (1980) Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology 31 (6) 410–417 Review.
[20]
Luther JA, Halmos KC, Tasker JG (2000) A slow transient potassium current expressed in a subset of neurosecretory neurons of the hypothalamic paraventricular nucleus. J Neurophysiol 84: 814–1825.
[21]
Qiu DL, Chu CP, Shirasaka T, Tsukino H, Nakao H, et al. (2005b) Corticotrophin-Releasing Factor Augments IH in Rat Hypothalamic Paraventricular Nucleus Parvocellular Neurons in vitro. J Neurophysiol 94 (1) 226–34.
[22]
De Souza EB (1987) Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci 7: 88–100.
[23]
Lawrence AJ, Krstew EV, Dautzenberg FM, Ruhmann A (2002) The highly selective CRF (2) receptor antagonist K41498 binds to presynaptic CRF (2) receptors in rat brain. Br J Pharmacol 136: 896–904.
[24]
Takigawa T, Alzheimer C (2003) Interplay between activation of GIRK current and deactivation of Ih modifies temporal integration of excitatory input in CA1 pyramidal cells. J Neurophysiol 89 (4) 2238–44.
[25]
Jin W, Lu Z (1999) Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry 38 (43) 14286–93.
[26]
Sun QQ, Huguenard JR, Prince DA (2002) Somatostatin inhibits thalamic network oscillations in vitro: Action on the GABAergic neurons of the reticular nucleus. J Neurosci 22 (13) 5374–5386.
[27]
Takigawa T, Alzheimer C (2002) Phasic and tonic attenuation of EPSC by inward rectifier K+ channels in the hippocampal pyramidal cells. J Physiolo (Lond) 539 (1) 67–75.
[28]
Wanat MJ, Hopf FW, Stuber GD, Phillips PEM, Bonci A (2008) Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Physiol 586 (8) 2157–2170.
[29]
Giesbrecht CJ, Mackay JP, Silveira HB, Urban JH, Colmers WF (2010) Countervailing Modulation of Ih by Neuropeptide Y and Corticotrophin-Releasing Factor in Basolateral Amygdala As a Possible Mechanism for Their Effects on Stress-Related Behaviors. J Neurosci 30 (50) 16970–16982.
[30]
Csaki A, Kocsis K, Halasz B, Jiss J (2000) Localization of putative glutamatergic/aspartatergic neurons projecting to the hypothalamic paraventricular nucleus studied by retrograde transport of [3H] Daspartate autoradiography. Neuroscience 101: 637–655.
[31]
Tasker JG, Dudek FE (1993) Local inhibitory synaptic inputs to neurones of the paraventricular nucleus in slices of rat hypothalamus. J Physiol (Lond) 469: 179–192.
[32]
Kannan H, Hayashida Y, Yamashita H (1989) Increase in sympathetic outflow by paraventricular nucleus stimulation in awake rats. Am J Physiol 256: R1325–R1330.
[33]
Martin DS, Segura T, Haywood JR (1991) Cardiovascular responses to bicuculline in the paraventricular nucleus of the rat. Hypertension 18: 48–55.
[34]
Park JB, Stern JE (2005) A tonic, gabaa receptor-mediated inhibitory postsynaptic current restrains firing activity in preautonomic and magnocellular neuroendocrine neurons of the paraventricular nucleus of the hypothalamus (pvn). FASEB J 19: A599–A599.
[35]
North RA (1989) Twelfth Gaddum memorial lecture. Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98 (1) 13–28 Review.
[36]
Slugg RM, Zheng SX, Fang Y, Kelly MJ, R？nnekleiv OK (2003) Baclofen inhibits guinea pig magnocellular neurones via activation of an inwardly rectifying K+ conductance. J Physiol 551 (Pt 1) 295–308.
[37]
Shirasaka T, Kannan H, Takasaki M (2007) Activation of a G protein-coupled inwardly rectifying K+ current and suppression of Ih contribute to dexmedetomidine-induced inhibition of rat hypothalamic paraventricular nucleus neurons. Anesthesiology 107 (4) 605–15.
[38]
Wotjak CT, Naruo T, Muraoka S, Simchen R, Landgraf R, et al. (2001) Forced swimming stimulates the expression of vosopressin and oxytocin in magnocellular neurons of the rat hypothalamic paraventricular nucleus. Eur J Neurosci 13: 2273–2281.
[39]
Nishioka T, Anselmo-Franci JA, Li P, Callahan MF, Morris M (1998) Stress increases oxytocin release within the hypothalamic paraventricular nucleus. Brain Res 781: 56–60.
[40]
Zheng J, Babygirija R, Bülbül M, Cerjak D, Ludwig K, et al. (2010) Hypothalamic oxytocin mediates adaptation mechanism against chronic stress in rats. Am J Physiol Gastrointest Live Physiol 299: G946–G953.
[41]
Neumann ID (2002) Involvement of the brain oxytocin system in stress coping: interactions with the hypothalamo-pituitary-adrenal axis. Prog Brain Res 139: 147–62 Review.
[42]
Windle RJ, Shanks N, Lightman SL, Ingram CD (1997) Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 138 (7) 2829–2834.
[43]
Blume A, Bosch OJ, Miklos S, Torner L, Wales L, et al. (2008) Oxytocin reduces anxiety via ERK1/2 activation: local effect within the rat hypothalamic paraventricular nucleus. Eur J Neurosci 27 (8) 1947–1956.
[44]
Nicolas N, Matthew W, Caroline D, Richard BJ (2011) Function and Pharmacology of Spinally-Projecting Sympathetic Pre- Autonomic Neurones in the Paraventricular Nucleus of the Hypothalamus. Current Neuropharmacology 9: 262–277.
[45]
Chu CP, Xu CJ, Kannan H, Qiu DL (2012) Corticotrophin-releasing factor inhibits neuromedin U mRNA expressing neuron in the rat hypothalamic paraventricular nucleus in vitro. Neurosci Lett 511: 79–83.
